Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Javier Szwarcberg
Observed names:
J Szwarcberg,
J. Szwarcberg,
Javier B Szwarcberg,
Szwarcberg Javier,
Szwarcberg, Javier
Institution:
Gilead Sciences (United States)
Observed institutions:
University of North Carolina at Chapel Hill,
Whitman-Walker Health,
Royal Brompton Hospital,
Gilead Sciences (United States),
Stanford University
OpenAlex ID:
A5112070394
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
2011
·
Paul W Noble
, Carlo Albera
, et al.
·
The Lancet
·
2,354
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial
2009
·
Talmadge E King
, Carlo Albera
, et al.
·
The Lancet
·
591
Six-Minute-Walk Test in Idiopathic Pulmonary Fibrosis: Test Validation and Minimal Clinically Important Difference
2011
·
Roland M. du Bois
, Derek Weycker
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
531
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
2012
·
Paul E Sax
, Edwin DeJesus
, et al.
·
The Lancet
·
481
Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis
2011
·
Roland M. du Bois
, Derek Weycker
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
462
PDF
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
2012
·
Edwin DeJesus
, Jürgen K Rockstroh
, et al.
·
The Lancet
·
372
Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction
2015
·
Ganesh Raghu
, Steven D. Nathan
, et al.
·
European Respiratory Journal
·
180
Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal Function
2012
·
Polina German
, Hui C. Liu
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
168
A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
2013
·
Andrew Zolopa
, Paul E. Sax
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
160
Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results
2013
·
Joel E. Gallant
, Ellen Koenig
, et al.
·
The Journal of Infectious Diseases
·
133
PDF
A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
2013
·
Jürgen K. Rockstroh
, Edwin DeJesus
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
133
A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results
2013
·
David A. Wohl
, Calvin Cohen
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
117
Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study
2016
·
Kathleen Squires
, Cissy Kityo
, et al.
·
The Lancet HIV
·
98
Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor–Based Initial Antiretroviral Therapy Among HIV-Infected Individuals
2015
·
Corrilynn O. Hileman
, Bruce Kinley
, et al.
·
The Journal of Infectious Diseases
·
89
PDF
A Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results
2013
·
Nathan Clumeck
, Jean-Michel Molina
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
80
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial
2014
·
Karen Tashima
, Gordon Crofoot
, et al.
·
AIDS Research and Therapy
·
66
PDF
A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection: 96-Week Results
2013
·
Richard Elion
, Jean-Michel Molina
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
43
Pleural involvement in chronic sarcoidosis detected by thoracic CT scanning.
2005
·
Javier B Szwarcberg
, Neville Glajchen
, et al.
·
PubMed
·
38
Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir.
2016
·
Thai Nguyen
, Ian McNicholl
, et al.
·
PubMed
·
28
Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate Week 144 Results
2015
·
Joel E. Gallant
, Ellen Koenig
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
28
Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients
2014
·
Rima Kulkarni
, Michael E. Abram
, et al.
·
HIV Clinical Trials
·
27
PDF
Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1–Infected Subjects: 48 Weeks Data
2014
·
A. Mills
, G. Crofoot
, et al.
·
HIV Clinical Trials
·
22
PDF
Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI
2017
·
Jose R. Arribas
, Edwin DeJesus
, et al.
·
HIV Clinical Trials
·
21
PDF
Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Efavirenz/Emtricitabine/Tenofovir DF in Antiretroviral-Naive Patients
2014
·
Kirsten L White
, Rima Kulkarni
, et al.
·
Antiviral Therapy
·
21
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI
2017
·
Anton Pozniak
, Jason Flamm
, et al.
·
HIV Clinical Trials
·
19
PDF
Show more works
View as search
Works count:
60
Citation count:
6,425
H-index:
22
I10-index:
33
Year
Topic
Type